Nurix Therapeutics shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $24 to $25.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics' stock price increased following Baird's decision to maintain an Outperform rating and raise its price target from $24 to $25.
April 11, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics' stock price is likely to experience a positive short-term impact due to Baird's maintained Outperform rating and increased price target.
Analyst ratings and price target adjustments are significant indicators for stock performance. Baird's decision to maintain an Outperform rating and raise the price target for Nurix Therapeutics directly influences investor sentiment and can lead to increased buying activity, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100